145 related articles for article (PubMed ID: 34088435)
21. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
[TBL] [Abstract][Full Text] [Related]
22. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
23. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
[TBL] [Abstract][Full Text] [Related]
24. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
26. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
[TBL] [Abstract][Full Text] [Related]
27. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
[TBL] [Abstract][Full Text] [Related]
28. Negative Biopsy Histology in Men With PI-RADS Score 5 in Daily Clinical Practice: Incidence of Granulomatous Prostatitis.
Pepe P; Pennisi M
Clin Genitourin Cancer; 2020 Dec; 18(6):e684-e687. PubMed ID: 32389459
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome.
Ryznarová Z; Keller J; Záleský M; Zachoval R; Čapek V; Malikova H
Neuro Endocrinol Lett; 2019 Mar; 40(1):41-50. PubMed ID: 31184822
[TBL] [Abstract][Full Text] [Related]
30. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
31. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
32. Cutoff Values of Prostate Imaging Reporting and Data System Version 2.1 Score in Men With Prostate-specific Antigen Level 4 to 10 ng/mL: Importance of Lesion Location.
Chen Y; Ruan M; Zhou B; Hu X; Wang H; Liu H; Liu J; Song G
Clin Genitourin Cancer; 2021 Aug; 19(4):288-295. PubMed ID: 33632569
[TBL] [Abstract][Full Text] [Related]
33. One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis.
Tafuri A; Ashrafi AN; Palmer S; Shakir A; Cacciamani GE; Iwata A; Iwata T; Cai J; Sali A; Gupta C; Medina LG; Stern MC; Duddalwar V; Aron M; Gill IS; Abreu A
World J Urol; 2020 Apr; 38(4):949-956. PubMed ID: 31175460
[TBL] [Abstract][Full Text] [Related]
34. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Gündoğdu E; Emekli E; Kebapçı M
Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
[TBL] [Abstract][Full Text] [Related]
37. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
[TBL] [Abstract][Full Text] [Related]
38. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice.
Sokhi HK; Padhani AR; Patel S; Pope A
Clin Radiol; 2020 Dec; 75(12):950-956. PubMed ID: 32919755
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic accuracy of
Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
